

# JUNE 2010 DUR BOARD MEETING MINUTES

**Date:** June 30, 2010

**Members Present:** Eichler, Brown, Burton, Sargent, Nagy, Crichton, Bradley, Fitzgerald, Cobb (phone)

**Others Present:** Roger Citron, Dan Peterson (Medicaid) Bobbi Renner (Mental Health Services), Kathy Novak (First Health), Lisa Wilkinson and Marcella Barnhill (Drug PA/CM unit), and various members of the public and representatives of drug manufacturers.

## **PDL Review:**

The Board made the following recommendations to the Department:

The Department proposed no changes to **GROUP 1** as all available chemical entities are preferred :

- **GLAUCOMA- CARBONIC ANHYDRASE INHIBITORS**

The Board agreed with the Department's proposal

The Department proposed no changes to the Formulary Committee's previous clinical recommendations.

The following classes were not reviewed because no **NEW** information was submitted:

- ADHD/CNS STIMULANTS
- SSRI's
- TRIPTANS
- HEMATOPOIETIC AGENTS
- ELECTROLYTE DEPLETERS
- NASAL CORTICOSTEROIDS
- ALPHA BLOCKERS for BPH
- ANDROGEN HORMONE INHIBITORS
- URINARY TRACT ANTISPASMODICS
- GLAUCOMA- ALPHA 2 ADRENERGICS
- GLAUCOMA- BETA BLOCKERS & COMBOS
- GLAUCOMA- PROSTAGLANDIN AGONISTS

The Board agreed with the Department's proposal

The Department reviewed the following classes as **NEW** information is known to exist:

- LONG ACTING NARCOTICS~Exaglo
- ATYPICAL ANTIPSYCHOTICS ~Fanapt, Saphris, Seroquel XR, Zyprexa, Zyprexa Relprevv
- NOVEL ANTIDEPRESSANTS~Savella
- GROWTH HORMONES~Tev-Tropin
- OPHTHALMIC QUINOLONES~Besivance
- OPHTHALMIC ANTIHISTAMINES~Bepreve
- OTIC QUINOLONES~Cetraxal

After hearing testimony and considering the new information presented, the Board discussed the red classes. The Board made the following recommendations:

### **Long Acting Narcotics:** Grandfather

Must have: 1 long acting morphine or 1 long acting oxycodone

May add: others; *May add Exalgo (drug reviewed at today's meeting)*

### **Atypical Antipsychotics:** Grandfather

Must have: Abilify (*change from 2009 to exclude Geodon from 'must have'*), Clozapine, Risperidone

Must have at least one of Seroquel or Zyprexa

May add: Symbyax, Invega, Fazaclo, Seroquel XR (*change from 2009 Seroquel XR was a must have*), Fanapt, and Saphris (*drugs reviewed at today's meeting*)

Do not add: Geodon

### **Novel Antidepressants:** Grandfather

Testimony was heard on Savella, but since it only has an indication for Fibromyalgia, the Board and Department decided not to add this drug to the preferred drug list at this time. No changes were made to the Novel Antidepressant recommendation from 2009. It was noted that Montana Medicaid does not cover nefazodone on either Medicaid or MHSP.

**Growth Hormone:** Grandfather

Therapeutic alternatives

**Ophthalmic Quinolones:**

Class effect (*change from 2009 which required products from 2<sup>nd</sup> and 3<sup>rd</sup> generation be made available*)

**Ophthalmic Antihistamines:**

Class effect

**Otic Quinolones:**

Class effect

The next meeting will be a regular DUR Board meeting. It will be September 22, 2010. The meeting was adjourned at 3:55.